In acute management for Kawasaki disease, recent studies are focused on treatment for patients who failed to respond to intravenous gamma globulin (IVGG) and high dose-aspirin. The addition of corticosteroids to IVGG and the use of TNF-alpha blockade are now under discussion. In long-term management, therapeutic angiogenesis is now applied for adult patients with ischemic hind limb or heart. It could be one of the therapeutic options for children and adolescents with Kawasaki disease and coronary artery abnormalities.